KRAKÓW, Poland, May 31, 2023 /PRNewswire/ -- Selvita S.A. [WSE: SLV], one of the largest contract research organization companies in Europe, has published a financial report for Q1 2023*. The Group is growing despite the demanding market, taking on numerous actions to strengthen sales and optimize the business.
Selvita, one of the largest preclinical CROs in Europe, continued its growth strategy with the completion of its new headquarters in Krakow, Poland.
Selvita Joins Scientist.com’s IND Package Pipeline Program
KRAKÓW, Poland, March 27, 2023 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the largest contract research organizations (CRO) in Europe, announced today completion of the construction of its new headquarters in Krakow, Poland. The newly built Selvita Research Centre is expected to strengthen Selvita's ability to provide top-notch research services in the field of drug discovery. This facility constitutes a key element of Selvita's Development Strategy for 2022-2025, putting a great emphasis on Company's further organic growth. The completion of the construction marks a significant milestone in Selvita's development journey.
KRAKOW, Poland, Sept. 6, 2022 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the largest contract research organizations (CRO) in Europe, reported its preliminary financial results for Q2 and H1 2022*. According to the preliminary estimates published, the Group continues its dynamic growth, already exceeding the assumptions of the development strategy for 2022-2025 presented in March.
Selvita appoints Dean Bornilla as Vice President of Sales, Head of North America
Selvita (WSE: SLV) - one of the largest preclinical contract research organizations in Europe, announced today the initiation of the construction of its own research centre in Krakow. The Company signed an agreement with the General Contractor – PORR S.A., which will be responsible for the execution of the investment.
Selvita (WSE: SLV) - one of the largest preclinical contract research organizations in Europe, announced today the initiation of the construction of its own research centre in Krakow. The Company signed an agreement with the General Contractor – PORR S.A., which will be responsible for the execution of the investment.
Selvita (WSE: SLV) - one of the largest preclinical contract research organizations in Europe, announced today the initiation of the construction of its own research centre in Krakow. The Company signed an agreement with the General Contractor – PORR S.A., which will be responsible for the execution of the investment.
MECHELEN, Belgium and KRAKOW, Poland, Jan. 4, 2021 /PRNewswire/ -- Galapagos NV [Euronext & NASDAQ: GLPG] and Selvita S.A. [WSE: SLV] announced today that the strategic transaction in which Selvita has acquired Fidelta from Galapagos has been completed.